This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
NCT ID: NCT00059722
Last Updated: 2016-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
160 participants
INTERVENTIONAL
2003-05-31
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer
NCT00090675
Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
NCT00242801
Iressa v BSC (Best Supportive Care) in First Line NSCLC
NCT00259064
Phase II Iressa & Carbo/Gem in NSCLC
NCT00264498
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
NCT00234468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ZD6474
Placebo
ZD1839
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prior histologic or cytologic confirmation of locally advanced or metastatic (IIIB/IV) NSCLC
Exclusion Criteria
* Any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic, need not be excluded)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genzyme, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Sciences & Operations
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Pine Bluff, Arkansas, United States
Research Site
Los Angeles, California, United States
Research Site
Palm Springs, California, United States
Research Site
San Diego, California, United States
Research Site
Boca Raton, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Orange Park, Florida, United States
Research Site
Coeur d'Alene, Idaho, United States
Research Site
Chicago, Illinois, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Shreveport, Louisiana, United States
Research Site
Saint Loius, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
Brooklyn, New York, United States
Research Site
New York, New York, United States
Research Site
Greenville, North Carolina, United States
Research Site
Bismarck, North Dakota, United States
Research Site
Madison, Wisconsin, United States
Research Site
Buenos Aires, , Argentina
Research Site
Mendoza, , Argentina
Research Site
Brussels, , Belgium
Research Site
Brussels (Jette), , Belgium
Research Site
Brussels (Woluwé-St-Lambert), , Belgium
Research Site
Edegem, , Belgium
Research Site
Liège, , Belgium
Research Site
Wilrijk, , Belgium
Research Site
Hamburg, City state of Hamburg, Germany
Research Site
Essen, North Rhine-Westphalia, Germany
Research Site
Mainz, Rhineland-Palatinate, Germany
Research Site
Berlin, State of Berlin, Germany
Research Site
Ryhope, Sunderland, Germany
Research Site
Berlin, , Germany
Research Site
Essen, , Germany
Research Site
Hamburg, , Germany
Research Site
Mainz, , Germany
Research Site
Bloemfontein, , South Africa
Research Site
Cape Town, , South Africa
Research Site
Durban, , South Africa
Research Site
Johannesburg, , South Africa
Research Site
Lyttelton Manor, , South Africa
Research Site
Parktown, , South Africa
Research Site
Port Elizabeth, , South Africa
Research Site
Pretoria, , South Africa
Research Site
Northwood, Middlesex, United Kingdom
Research Site
Cardiff, South Glamorgan, United Kingdom
Research Site
Edinburgh, , United Kingdom
Research Site
Leeds, , United Kingdom
Research Site
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6474IL/0003
Identifier Type: -
Identifier Source: org_study_id
NCT00072423
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.